BTG acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company also manufactures and commercializes therapeutic ultrasound devices, and roxwood systems, as well as develops venous thrombus management devices. British Technology Group International that began operation in 1948 became BTG in March 1995. Its headquarters is in London in the United Kingdom.

Provides research on animal and plant healthcare, material sciences and biotechnology

DSM IP Assets BV, a subsidiary of Koninklijke DSM NV, is a company headquartered in Heerlen, the Netherlands, that develops and produces nutrition, pharmacy & material science products.

MicroProbe develops, manufactures and supports wafer-test probe card products. They help semiconductor manufacturers bring new generations of non-memory devices to market faster and more economically. They include microprocessors, graphic processors, mobile RF and SoCs, and analog and mixed-signal products – imperative drivers of today’s sophisticated, multi-functional consumer mobile devices.

SCYNEXIS, Inc. operates as a drug discovery and development company in the United States and internationally. It engages in drug discovery, development, and manufacturing projects in various areas, such as antibacterials, antifungals, antiparasitics, antivirals, carbohydrates, central nervous system, controlled substances, kinases, natural products, neglected diseases, nuclear hormones, nucleosides, oncology, ophthalmology, pain, and prodrugs. The company offers SCY-635, a drug that is used for patients who are chronically infected with genotype 1 hepatitis C virus. It also provides contract research solutions, including medicinal chemistry, discovery biology, ADMET-PK, bioanalysis and analytical chemistry, process chemistry, and cGMP manufacturing. The company delivers drug pipeline solutions to pharmaceutical, health, and life science partners. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is based in Durham, North Carolina.

Domantis Ltd. develops antibody molecules. Domantis Ltd. offers dual targeting human domain antibodies, which are used against cytokine targets for inflammatory diseases, tumour antigens present on the same tumour cells, and tumour growth/angiogenic factors for solid tumours; human domain antibodies with tailored serum half-life that are customized to achieve the desired therapeutic effect; human domain antibodies for diverse therapeutic targets, which are suited to inhibit receptor targets; and injectable and non-injectable human domain antibodies that treat diseases of the lung, as well as disorders of the gastro-intestinal tract.

Daewoong Pharmaceutical Co., Ltd (Korean: 대웅제약) is a Seoul, South Korea-based bioengineering company operating as a subsidiary of Daewoong Co., Ltd., a global health care group. Daewoong Pharmaceutical primarily engages in the manufacture of pharmaceutical products in South Korea, including prescription and over-the-counter healthcare products.

BioMendic LLC provides research and treatment of acute wounds, burns, and inflammatory skin conditions. The company was founded by Karen M. McGuire and is headquartered in Rootstown, OH.

Gen-Probe Incorporated develops, manufactures, and markets nucleic acid probe-based products used for the clinical diagnosis of human diseases, and for screening donated human blood in North America and internationally. The company markets and sells its clinical diagnostic products in the United States directly and outside the United States primarily through distributors, as well as through its direct sales force, and the company also markets and sells its other products through collaborative partners. The company's blood screening products are marketed and distributed worldwide by Novartis. In addition, the company has agreements with Siemens (as assignee of Bayer Corporation), bioMérieux, Inc., or bioMérieux, and Fujirebio, Inc., through its subsidiary Rebio Gen, Inc., or Rebio Gen, to market products in various overseas markets. The company is developing NAT assays and instruments for the detection of harmful pathogens in the environment and biopharmaceutical and beverage manufacturing processes. The company has entered into collaboration agreements with GE Infrastructure Water and Process Technologies, or GEI, a unit of General Electric Company, and Millipore Corporation, or Millipore, under which the company would be primarily responsible for developing and manufacturing assays for exclusive use or sale by its collaborative partners in specified fields with in the industrial testing market. Products The company has applied its core technologies to develop multiple product lines, all of which utilize its expertise in NAT probes, sample collection and processing. The company categorizes its products into clinical diagnostic products and blood screening products. Clinical Diagnostic Products Within its clinical diagnostic product group, the company has developed products for the detection of non-viral and viral microorganisms and for the detection of markers for cancer. Clinical Diagnostic Products for the Detection of Non-Viral Microorganisms The company has developed FDA-approved amplified and non-amplified NAT assays that detect non-viral micro-organisms primarily for use in clinical diagnostics. The company's principal products for the detection of non-viral microorganisms include its non-amplified AccuProbe and PACE family of products and its amplified Mycobacterium Tuberculosis Direct Test and amplified APTIMA products. AccuProbe Products: The company's AccuProbe Culture Identification products are tools for the identification of mycobacterial, fungal and bacterial pathogens, with sensitivities and specificities approaching 100% in most cases. These products allow for the detection of target organisms from primary cultures, eliminating the additional labor of purifying secondary cultures. All AccuProbe Culture Identification assays are based on its HPA technology. As part of its AccuProbe Culture Identification product line, the company also has developed a procedure to detect GBS from broth culture. Group A Streptococcus Direct: The Group A Streptococcus Direct Test, or GASDirect assay, is a NAT assay for the direct detection of Streptococcus pyogenes in one hour from a throat swab. PACE Product Family: The company's PACE 2C offers the testing for both chlamydia infections and gonorrhea from a single patient specimen.

US Agriculture LLC provides investment services. It operates and manage farmland assets and portfolios, develop and implement farmland investment strategies, underwrite and acquire farmland assets across a variety of regions and crop types, develop and implement efficient and effective reporting processes, design and implement investment policies, develop and implement asset allocation strategies, create and implement tools for market and asset targeting, and create and implement portfolio optimization tools and processes. The company was founded in 2015 and is headquartered in Indianapolis, IN.

Cornwall Resources, Inc. engages in the provision of industrial construction services to the oil and gas industry. The company was founded in 1992 and is headquartered in Las Vegas, NV.

Merz Pharma GmbH & Co. KGaA is an innovative and international healthcare company with its own research and development department. It focuses on drugs for the treatment of illness in the fields of neurology and psychiatry. The company is bundling the activities of its subsidiaries Merz Pharmaceuticals, Merz Consumer Care, Merz Dental, and Merz Hygiene, with products ranging from prescription drugs and OTC products for health and wellness, materials for dentists and dental technicians to hygienic products for medical disinfection and cleaning.\nThe units of Merz Group Services, the fith Merz subsidiary, include Human Resources, Supply Chain/Purchasing, Information Technology (IT), Technical Operations and Finances/Controlling.

Toyama Chemical Co., Ltd. develops and supplies pharmaceutical products. It engages in information collection, clinical development of pharmaceuticals and distribution of healthcare products. The company was founded on November 15, 1936 and is headquartered in Tokyo, Japan.

Taisho Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following divisions: Self-Medication, Prescription Pharmaceutical and Overseas Development. The Self-Medication division deals with the research, development, and production of over-the-counter (OTC) drugs, medical supplies, food for specific health use, and hygiene products. The Prescription Pharmaceutical division handles research and development of new drugs in the fields of central nervous system diseases, metabolic diseases, infectious diseases, and inflammatory diseases. The Overseas Development division markets energy drinks and OTC pharmaceuticals overseas. The company was founded on October 12, 1912 and is headquartered in Tokyo, Japan.

AMRI (Albany Molecular Research Inc.) is a contract research and manufacturing organization that provides drug discovery, development, cGMP manufacturing and aseptic fill and finish to the pharmaceutical and biotechnology industries. Founded over 27 years ago, AMRI operates in the United States, Europe and Asia, with its headquarters located in Albany, New York. AMRI has announced deals and collaborations with such companies as Pfizer Inc., Merck & Co., Eli Lilly and Co., Takeda, Genentech, Bristol-Myers Squibb Co. and GE.

Part of The Est��e Lauder Companies, Inc., ELC Management LLC is an American company that provides management services.